The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global VEGF Inhibitor Drugs Market Research Report 2025
Synopsis
Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells.
The global VEGF Inhibitor Drugs market was valued at US$ 8271 million in 2023 and is anticipated to reach US$ 14460 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for VEGF Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF Inhibitor Drugs.
Report Scope
The VEGF Inhibitor Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VEGF Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VEGF Inhibitor Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
Bayer AG
Eli Lilly & Company
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of VEGF Inhibitor Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells.
The global VEGF Inhibitor Drugs market was valued at US$ 8271 million in 2023 and is anticipated to reach US$ 14460 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for VEGF Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VEGF Inhibitor Drugs.
Report Scope
The VEGF Inhibitor Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global VEGF Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VEGF Inhibitor Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis AG
GlaxoSmithKline plc
Sanofi
AstraZeneca plc
Bristol-Myers-Squibb Company
Genentech, Inc. (Roche)
Merck & Co., Inc.
Bayer AG
Eli Lilly & Company
Segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Segment by Application
Oncology
Ophthalmology
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of VEGF Inhibitor Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global VEGF Inhibitor Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tyrosine Kinase Inhibitors
1.2.3 Monoclonal Antibodies
1.2.4 Others
1.3 Market by Application
1.3.1 Global VEGF Inhibitor Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Ophthalmology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global VEGF Inhibitor Drugs Market Perspective (2019-2030)
2.2 VEGF Inhibitor Drugs Growth Trends by Region
2.2.1 Global VEGF Inhibitor Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 VEGF Inhibitor Drugs Historic Market Size by Region (2019-2024)
2.2.3 VEGF Inhibitor Drugs Forecasted Market Size by Region (2025-2030)
2.3 VEGF Inhibitor Drugs Market Dynamics
2.3.1 VEGF Inhibitor Drugs Industry Trends
2.3.2 VEGF Inhibitor Drugs Market Drivers
2.3.3 VEGF Inhibitor Drugs Market Challenges
2.3.4 VEGF Inhibitor Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top VEGF Inhibitor Drugs Players by Revenue
3.1.1 Global Top VEGF Inhibitor Drugs Players by Revenue (2019-2024)
3.1.2 Global VEGF Inhibitor Drugs Revenue Market Share by Players (2019-2024)
3.2 Global VEGF Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by VEGF Inhibitor Drugs Revenue
3.4 Global VEGF Inhibitor Drugs Market Concentration Ratio
3.4.1 Global VEGF Inhibitor Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by VEGF Inhibitor Drugs Revenue in 2023
3.5 VEGF Inhibitor Drugs Key Players Head office and Area Served
3.6 Key Players VEGF Inhibitor Drugs Product Solution and Service
3.7 Date of Enter into VEGF Inhibitor Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 VEGF Inhibitor Drugs Breakdown Data by Type
4.1 Global VEGF Inhibitor Drugs Historic Market Size by Type (2019-2024)
4.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2025-2030)
5 VEGF Inhibitor Drugs Breakdown Data by Application
5.1 Global VEGF Inhibitor Drugs Historic Market Size by Application (2019-2024)
5.2 Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America VEGF Inhibitor Drugs Market Size (2019-2030)
6.2 North America VEGF Inhibitor Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America VEGF Inhibitor Drugs Market Size by Country (2019-2024)
6.4 North America VEGF Inhibitor Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe VEGF Inhibitor Drugs Market Size (2019-2030)
7.2 Europe VEGF Inhibitor Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe VEGF Inhibitor Drugs Market Size by Country (2019-2024)
7.4 Europe VEGF Inhibitor Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific VEGF Inhibitor Drugs Market Size (2019-2030)
8.2 Asia-Pacific VEGF Inhibitor Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America VEGF Inhibitor Drugs Market Size (2019-2030)
9.2 Latin America VEGF Inhibitor Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America VEGF Inhibitor Drugs Market Size by Country (2019-2024)
9.4 Latin America VEGF Inhibitor Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa VEGF Inhibitor Drugs Market Size (2019-2030)
10.2 Middle East & Africa VEGF Inhibitor Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer VEGF Inhibitor Drugs Introduction
11.1.4 Pfizer Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG VEGF Inhibitor Drugs Introduction
11.2.4 Novartis AG Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.2.5 Novartis AG Recent Development
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Company Detail
11.3.2 GlaxoSmithKline plc Business Overview
11.3.3 GlaxoSmithKline plc VEGF Inhibitor Drugs Introduction
11.3.4 GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.3.5 GlaxoSmithKline plc Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi VEGF Inhibitor Drugs Introduction
11.4.4 Sanofi Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 AstraZeneca plc
11.5.1 AstraZeneca plc Company Detail
11.5.2 AstraZeneca plc Business Overview
11.5.3 AstraZeneca plc VEGF Inhibitor Drugs Introduction
11.5.4 AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.5.5 AstraZeneca plc Recent Development
11.6 Bristol-Myers-Squibb Company
11.6.1 Bristol-Myers-Squibb Company Company Detail
11.6.2 Bristol-Myers-Squibb Company Business Overview
11.6.3 Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Introduction
11.6.4 Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.6.5 Bristol-Myers-Squibb Company Recent Development
11.7 Genentech, Inc. (Roche)
11.7.1 Genentech, Inc. (Roche) Company Detail
11.7.2 Genentech, Inc. (Roche) Business Overview
11.7.3 Genentech, Inc. (Roche) VEGF Inhibitor Drugs Introduction
11.7.4 Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.7.5 Genentech, Inc. (Roche) Recent Development
11.8 Merck & Co., Inc.
11.8.1 Merck & Co., Inc. Company Detail
11.8.2 Merck & Co., Inc. Business Overview
11.8.3 Merck & Co., Inc. VEGF Inhibitor Drugs Introduction
11.8.4 Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.8.5 Merck & Co., Inc. Recent Development
11.9 Bayer AG
11.9.1 Bayer AG Company Detail
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG VEGF Inhibitor Drugs Introduction
11.9.4 Bayer AG Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.9.5 Bayer AG Recent Development
11.10 Eli Lilly & Company
11.10.1 Eli Lilly & Company Company Detail
11.10.2 Eli Lilly & Company Business Overview
11.10.3 Eli Lilly & Company VEGF Inhibitor Drugs Introduction
11.10.4 Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2019-2024)
11.10.5 Eli Lilly & Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global VEGF Inhibitor Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Tyrosine Kinase Inhibitors
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Others
Table 5. Global VEGF Inhibitor Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global VEGF Inhibitor Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global VEGF Inhibitor Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global VEGF Inhibitor Drugs Market Share by Region (2019-2024)
Table 9. Global VEGF Inhibitor Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global VEGF Inhibitor Drugs Market Share by Region (2025-2030)
Table 11. VEGF Inhibitor Drugs Market Trends
Table 12. VEGF Inhibitor Drugs Market Drivers
Table 13. VEGF Inhibitor Drugs Market Challenges
Table 14. VEGF Inhibitor Drugs Market Restraints
Table 15. Global VEGF Inhibitor Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global VEGF Inhibitor Drugs Market Share by Players (2019-2024)
Table 17. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2023)
Table 18. Ranking of Global Top VEGF Inhibitor Drugs Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by VEGF Inhibitor Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players VEGF Inhibitor Drugs Product Solution and Service
Table 22. Date of Enter into VEGF Inhibitor Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global VEGF Inhibitor Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2019-2024)
Table 26. Global VEGF Inhibitor Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global VEGF Inhibitor Drugs Revenue Market Share by Type (2025-2030)
Table 28. Global VEGF Inhibitor Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2019-2024)
Table 30. Global VEGF Inhibitor Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global VEGF Inhibitor Drugs Revenue Market Share by Application (2025-2030)
Table 32. North America VEGF Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America VEGF Inhibitor Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America VEGF Inhibitor Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe VEGF Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe VEGF Inhibitor Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe VEGF Inhibitor Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific VEGF Inhibitor Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific VEGF Inhibitor Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America VEGF Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America VEGF Inhibitor Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America VEGF Inhibitor Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa VEGF Inhibitor Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa VEGF Inhibitor Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Pfizer Company Detail
Table 48. Pfizer Business Overview
Table 49. Pfizer VEGF Inhibitor Drugs Product
Table 50. Pfizer Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 51. Pfizer Recent Development
Table 52. Novartis AG Company Detail
Table 53. Novartis AG Business Overview
Table 54. Novartis AG VEGF Inhibitor Drugs Product
Table 55. Novartis AG Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 56. Novartis AG Recent Development
Table 57. GlaxoSmithKline plc Company Detail
Table 58. GlaxoSmithKline plc Business Overview
Table 59. GlaxoSmithKline plc VEGF Inhibitor Drugs Product
Table 60. GlaxoSmithKline plc Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 61. GlaxoSmithKline plc Recent Development
Table 62. Sanofi Company Detail
Table 63. Sanofi Business Overview
Table 64. Sanofi VEGF Inhibitor Drugs Product
Table 65. Sanofi Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 66. Sanofi Recent Development
Table 67. AstraZeneca plc Company Detail
Table 68. AstraZeneca plc Business Overview
Table 69. AstraZeneca plc VEGF Inhibitor Drugs Product
Table 70. AstraZeneca plc Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 71. AstraZeneca plc Recent Development
Table 72. Bristol-Myers-Squibb Company Company Detail
Table 73. Bristol-Myers-Squibb Company Business Overview
Table 74. Bristol-Myers-Squibb Company VEGF Inhibitor Drugs Product
Table 75. Bristol-Myers-Squibb Company Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 76. Bristol-Myers-Squibb Company Recent Development
Table 77. Genentech, Inc. (Roche) Company Detail
Table 78. Genentech, Inc. (Roche) Business Overview
Table 79. Genentech, Inc. (Roche) VEGF Inhibitor Drugs Product
Table 80. Genentech, Inc. (Roche) Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 81. Genentech, Inc. (Roche) Recent Development
Table 82. Merck & Co., Inc. Company Detail
Table 83. Merck & Co., Inc. Business Overview
Table 84. Merck & Co., Inc. VEGF Inhibitor Drugs Product
Table 85. Merck & Co., Inc. Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 86. Merck & Co., Inc. Recent Development
Table 87. Bayer AG Company Detail
Table 88. Bayer AG Business Overview
Table 89. Bayer AG VEGF Inhibitor Drugs Product
Table 90. Bayer AG Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 91. Bayer AG Recent Development
Table 92. Eli Lilly & Company Company Detail
Table 93. Eli Lilly & Company Business Overview
Table 94. Eli Lilly & Company VEGF Inhibitor Drugs Product
Table 95. Eli Lilly & Company Revenue in VEGF Inhibitor Drugs Business (2019-2024) & (US$ Million)
Table 96. Eli Lilly & Company Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global VEGF Inhibitor Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global VEGF Inhibitor Drugs Market Share by Type: 2023 VS 2030
Figure 3. Tyrosine Kinase Inhibitors Features
Figure 4. Monoclonal Antibodies Features
Figure 5. Others Features
Figure 6. Global VEGF Inhibitor Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global VEGF Inhibitor Drugs Market Share by Application: 2023 VS 2030
Figure 8. Oncology Case Studies
Figure 9. Ophthalmology Case Studies
Figure 10. Others Case Studies
Figure 11. VEGF Inhibitor Drugs Report Years Considered
Figure 12. Global VEGF Inhibitor Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global VEGF Inhibitor Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global VEGF Inhibitor Drugs Market Share by Region: 2023 VS 2030
Figure 15. Global VEGF Inhibitor Drugs Market Share by Players in 2023
Figure 16. Global Top VEGF Inhibitor Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VEGF Inhibitor Drugs as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by VEGF Inhibitor Drugs Revenue in 2023
Figure 18. North America VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America VEGF Inhibitor Drugs Market Share by Country (2019-2030)
Figure 20. United States VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe VEGF Inhibitor Drugs Market Share by Country (2019-2030)
Figure 24. Germany VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific VEGF Inhibitor Drugs Market Share by Region (2019-2030)
Figure 32. China VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America VEGF Inhibitor Drugs Market Share by Country (2019-2030)
Figure 40. Mexico VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa VEGF Inhibitor Drugs Market Share by Country (2019-2030)
Figure 44. Turkey VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia VEGF Inhibitor Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Pfizer Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 47. Novartis AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 48. GlaxoSmithKline plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 49. Sanofi Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 50. AstraZeneca plc Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 51. Bristol-Myers-Squibb Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 52. Genentech, Inc. (Roche) Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 53. Merck & Co., Inc. Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 54. Bayer AG Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 55. Eli Lilly & Company Revenue Growth Rate in VEGF Inhibitor Drugs Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
